676 related articles for article (PubMed ID: 31409745)
1. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
3. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
7. Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing.
Kim JE; Chun SM; Hong YS; Kim KP; Kim SY; Kim J; Sung CO; Cho EJ; Kim TW; Jang SJ
J Mol Diagn; 2019 Mar; 21(2):241-250. PubMed ID: 30389464
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
[TBL] [Abstract][Full Text] [Related]
9. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
[TBL] [Abstract][Full Text] [Related]
10. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.
Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N
J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449
[TBL] [Abstract][Full Text] [Related]
11. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.
Trabucco SE; Gowen K; Maund SL; Sanford E; Fabrizio DA; Hall MJ; Yakirevich E; Gregg JP; Stephens PJ; Frampton GM; Hegde PS; Miller VA; Ross JS; Hartmaier RJ; Huang SA; Sun JX
J Mol Diagn; 2019 Nov; 21(6):1053-1066. PubMed ID: 31445211
[TBL] [Abstract][Full Text] [Related]
12. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
[TBL] [Abstract][Full Text] [Related]
14. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability status is determined by targeted sequencing with MSIcall in 25 cancer types.
Hirotsu Y; Nagakubo Y; Amemiya K; Oyama T; Mochizuki H; Omata M
Clin Chim Acta; 2020 Mar; 502():207-213. PubMed ID: 31730810
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
[TBL] [Abstract][Full Text] [Related]
17. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
18. Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples.
Wang M; Chen X; Dai Y; Wu D; Liu F; Yang Z; Song B; Xie L; Yang L; Zhao W; Zhang C; Shen W; Fan C; Teng C; Zhao X; Gao N; Shang D; Zhao G; Xin T
Mol Diagn Ther; 2022 May; 26(3):309-322. PubMed ID: 35305253
[TBL] [Abstract][Full Text] [Related]
19. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.
Kroeze LI; de Voer RM; Kamping EJ; von Rhein D; Jansen EAM; Hermsen MJW; Barberis MCP; Botling J; Garrido-Martin EM; Haller F; Lacroix L; Maes B; Merkelbach-Bruse S; Pestinger V; Pfarr N; Stenzinger A; van den Heuvel MM; Grünberg K; Ligtenberg MJL
J Mol Diagn; 2020 Jun; 22(6):757-769. PubMed ID: 32205293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]